rx 821002 has been researched along with Ataxia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McAllister, KH; Rey, B | 1 |
| Durcan, MJ; Linnoila, M; Lister, RG | 1 |
2 other study(ies) available for rx 821002 and Ataxia
| Article | Year |
|---|---|
Clozapine reversal of the deficits in coordinated movement induced by D2 receptor blockade does not depend upon antagonism of alpha2 adrenoceptors.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Ataxia; Clozapine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Idazoxan; Loxapine; Male; Muscarinic Antagonists; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Scopolamine; Yohimbine | 1999 |
Evidence for central alpha-2 adrenoceptors, not imidazoline binding sites, mediating the ethanol-attenuating properties of alpha-2 adrenoceptor antagonists.
Topics: Adrenergic alpha-Antagonists; Animals; Ataxia; Body Temperature; Brain; Dioxanes; Ethanol; Idazoxan; Imidazoles; Imidazoline Receptors; Male; Mice; Motor Activity; Quinolizines; Receptors, Adrenergic, alpha; Receptors, Drug | 1991 |